Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TRILLION ENERGY’S GULUC-2 WELL TESTS 16.35 MMCF/DAY (click to learn more) Aton (V.AAN) Reports Diamond Drill Results, Including 1.38 g/t Au Eq & 8.20% Zn over 22.5m from Surface (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Y-mAbs Therapeutics Inc. YMAB

Healthcare Biotechnology
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:YMAB)

Fundamentals Snapshot (NDAQ:YMAB)

Current News (NDAQ:YMAB)

Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023

GlobeNewswire 8 days ago

FINAL DEADLINE ALERT: Scott+Scott Attorneys at Law LLP Reminds Investors That a Securities Class Action Has Been Filed Against Y-mAbs Therapeutics, Inc. (YMAB) Lead Plaintiff Deadline is March 20, 2023

Newsfile 9 days ago

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 20, 2023 in Y-mAbs Lawsuit - YMAB

Newsfile 9 days ago

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Y-mAbs Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile 9 days ago

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Y-mAbs Investors of a Lead Plaintiff Deadline of March 20, 2023

PR Newswire 10 days ago

YMAB FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm's Attorneys Before Mar. 20th Deadline in Securities Fraud Class Action

Newsfile 10 days ago

1 DAY UNTIL DEADLINE: Scott+Scott Attorneys at Law LLP Reminds Investors That a Securities Class Action Has Been Filed Against Y-mAbs Therapeutics, Inc. (YMAB) Lead Plaintiff Deadline is March 20, 2023

Newsfile 10 days ago

Y-mAbs Shareholder Notice

Newsfile 11 days ago

Y-MABS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options

PR Newswire 12 days ago
View More News ››

Opinion & Analysis (NDAQ:YMAB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:YMAB)

RE:nice results

The trend is our friend on this one.
Joe455 - April 1, 2022

nice results

sweet
Karren411 - March 28, 2022
View more Bullboard ››

i3 Energy Plc.

i3 Energy Plc.

i3 Energy is an oil and gas Company with a low cost, diversified, growing production base in Canada's most prolific ...
View More »